How are Cosmetic Products Regulated in the United Arab Emirates?
The United Arab Emirates (UAE) are an emerging market for the beauty industry. Cosmetics and personal care products supplied or sold in the UAE must comply with the health and safety requirements set out in UAE legislation. Overall, the process for importing a cosmetic product into the UAE market from the European Union can be quite straightforward since the UAE has aligned several of its requirements with the European Cosmetic Regulation.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


The Emirates Authority for Standardization and Metrology (ESMA) is the entity responsible for drafting regulations and defining their requirements at the federal level, regulating, and supervising the personal care sector in the United Arab Emirates. Market surveillance and inspections are the responsibility of the Municipalities (one for each Emirate).

Cosmetics and personal care products must comply with health and safety requirements that are set out in the GSO 1943/2016 (Cosmetic ProductsSafety Requirements of Cosmetic and Personal Care Products). The UAE cosmetics Regulation applies to all cosmetic products supplied or sold in the UAE.

According to the Regulation, a cosmetic product is defined as “any substance or mixture made for the use and contact of the external organs and parts of the body (such as the skin, hair, nails, lips, teeth, genitals or the mucosa of oral cavity) for the purpose of cleaning or perfuming them, changing their appearance, or enhancing their smell, or protecting or keeping them in the best shape“. Medical products (used to cure diseases) and devices and tools that go together with cosmetics are excluded from the scope of the Cosmetics Law.

The Emirates Conformity Assessment Scheme (ECAS) is a product certification scheme implemented by ESMA, for all imported and manufactured (locally) cosmetic and personal care products. Before products are made available in the UAE market (imported or locally manufactured), ECAS ensures that they follow the applicable technical standards (related to health, packaging, labelling, and metrology). If the cosmetic product is compliant, ESMA issues an ECAS Certificate of Conformity. Without this certificate, a product is not allowed to enter the country or be distributed.

After having the certificate, cosmetic products need to be registered with both the relevant Municipality (in which the product is intended to be sold) and ESMA. If in one hand, the Municipality registration allows the product to be sold in a retail chain, on the other, the ESMA registration allows the product to be imported into the country, at the port of entry. Only a company incorporated in the UAE may perform the registration process (e.g., local importer, manufacturer, distributer). Therefore, a local representative is needed for registration, as the company needs to be registered locally with a license for ‘general trading’ to register products in UAE.

The process of registration enables the Consumer Products Safety Section (CPSS) body to collect all the information necessary to determine the safety of a cosmetic product. It is only possible to manufacture, import, export, promote or distribute a cosmetic product in UAE if it is registered and compliant with regulations.

When the registration process is completed, the application process follows. An application form is submitted along with the following information:

  • Picture and artwork of the product illustrating the required information (including shelf life, batch lot number, period after opening);
  • Free Sale Certificate from the country of origin (imported products);
  • Analysis and Ingredients Report from the manufacturing company (in addition to the physical, chemical and microbiological analysis of the product, detailed information about its components and concentrations);
  • Laboratory test report related to certain heavy metal and preservatives and microbiology tests from an accredited laboratory (tests may vary).

The labelling of cosmetics and personal care product needs to be in English and/or Arabic and must bear accurate, scientifically or laboratory verified and non-misleading information. For example, product function and/or use; warning instructions and precautionary information; and storage instructions for safe use needs to be indicated on the label. Medical claims are prohibited.

Product ingredients must be listed on the container or on the product itself (if no container is used). Allergens need to be included in the ingredients list (that appear on the label of container packages). If a perfume contains an aromatic allergenic substance at a concentration above 0.001%, it must be indicated in the list of substances that compose the product (container’s packaging).

The UAE regulation includes positive, negative and restricted lists of ingredients, that are overall aligned with the lists of Annexes the EU Cosmetics Regulation (Regulation (EC) No 1223/2009), except for four specific ingredients (included in the restricted list): alpha-hydroxy acids; urea; vitamin A and its esters (retinyl acetate, retinyl palmitate, cetylpyridinium chloride).

There are several other requirements that cosmetic products must follow in the UAE such as being completely free from pork and all its derivatives, complying with all safety tests required by legislation, and being safe when used under normal and foreseeable conditions of use. Cosmetic products made available in the UAE market cannot contain graphics, images or phrases that are inconsistent with Islamic traditions and prevailing social values in GCC (Gulf Cooperation Council) countries.

If you need more information regarding the UAE regulatory framework or any other subject, do not hesitate to contact us at


  1. GSO 12/FDS 1943:2018. Cosmetic Products – Safety Requirements of Cosmetics and Personal Care Products. GCC Standardization Organization (GSO). Available at:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »